RESUMO
Multiple Sclerosis is a chronic neurological disease characterized by demyelination and axonal loss. This pathology, still largely of unknown etiology, carries within it a complex series of etiopathogenetic components of which it is difficult to trace the origin. An inflammatory state is likely to be the basis of the pathology. Crucial elements of the inflammatory process are the interactions between platelets and mast cells as well as the bacterial component of the intestinal microbiota. In addition, the involvement of mast cells in autoimmune demyelinating diseases has been shown. The present work tries to hang up on that Ariadne's thread which, in the molecular complexity of the interactions between mast cells, platelets, microbiota and inflammation, characterizes Multiple Sclerosis and attempts to bring the pathology back to the causal determinism of psychopathological phenomenology. Therefore, we consider the possibility that the original error of Multiple Sclerosis can be investigated in the genetic origin of the depressive pathology.
Assuntos
Microbioma Gastrointestinal , Esclerose Múltipla , Plaquetas/patologia , Humanos , Inflamação , Mastócitos , Transtornos do Humor , Esclerose Múltipla/patologia , Células-Tronco/patologiaRESUMO
The bidirectional interaction between the gut microbiota (GM) and the Central Nervous System, the so-called gut microbiota brain axis (GMBA), deeply affects brain function and has an important impact on the development of neurodegenerative diseases. In Parkinson's disease (PD), gastrointestinal symptoms often precede the onset of motor and non-motor manifestations, and alterations in the GM composition accompany disease pathogenesis. Several studies have been conducted to unravel the role of dysbiosis and intestinal permeability in PD onset and progression, but the therapeutic and diagnostic applications of GM modifying approaches remain to be fully elucidated. After a brief introduction on the involvement of GMBA in the disease, we present evidence for GM alterations and leaky gut in PD patients. According to these data, we then review the potential of GM-based signatures to serve as disease biomarkers and we highlight the emerging role of probiotics, prebiotics, antibiotics, dietary interventions, and fecal microbiota transplantation as supportive therapeutic approaches in PD. Finally, we analyze the mutual influence between commonly prescribed PD medications and gut-microbiota, and we offer insights on the involvement also of nasal and oral microbiota in PD pathology, thus providing a comprehensive and up-to-date overview on the role of microbial features in disease diagnosis and treatment.
Assuntos
Microbioma Gastrointestinal , Doença de Parkinson , Humanos , Microbioma Gastrointestinal/fisiologia , Doença de Parkinson/diagnóstico , Doença de Parkinson/terapia , Doença de Parkinson/patologia , Disbiose/terapia , Antibacterianos , BiomarcadoresRESUMO
In this work, we propose that for further studies of the physiopathology and treatment for inflammatory bowel diseases, an integral view of the conditions, including the triad of microbiota-heat shock proteins (HSPs)-probiotics, ought to be considered. Microbiota is the complex microbial flora that resides in the gut, affecting not only gut functions but also the health status of the whole body. Alteration in the microbiota's composition has been implicated in a variety of pathological conditions (e.g., ulcerative colitis, UC), involving both gut and extra-intestinal tissues and organs. Some of these pathologies are also associated with an altered expression of HSPs (chaperones) and this is the reason why they may be considered chaperonopathies. Probiotics, which are live microorganisms able to restore the correct, healthy equilibrium of microbiota composition, can ameliorate symptoms in patients suffering from UC and modulate expression levels of HSPs. However, currently probiotic therapy follows ex-adiuvantibus criteria, i.e., treatments with beneficial effects but whose mechanism of action is unknown, which should be changed so the probiotics needed in each case are predetermined on the basis of the patient's microbiota. Consequently, efforts are necessary to develop diagnostic tools for elucidating levels and distribution of HSPs and the microbiota composition (microbiota fingerprint) of each subject and, thus, guide specific probiotic therapy, tailored to meet the needs of the patient. Microbiota fingerprinting ought to include molecular biology techniques for sequencing highly conserved DNA, e.g., genes encoding 16S RNA, for species identification and, in addition, quantification of each relevant microbe.
Assuntos
Colite Ulcerativa/microbiologia , Colite Ulcerativa/terapia , Trato Gastrointestinal/microbiologia , Microbiota , Probióticos/administração & dosagem , Colite Ulcerativa/fisiopatologia , Humanos , Chaperonas Moleculares/metabolismoRESUMO
Ageing is a biological phenomenon that determines the impairment of cognitive performances, in particular, affecting memory. Inflammation and cellular senescence are known to be involved in the pathogenesis of cognitive decline. The gut microbiota-brain axis could exert a critical role in influencing brain homeostasis during ageing, modulating neuroinflammation, and possibly leading to inflammaging. Due to their anti-ageing properties, medicinal mushrooms can be utilised as a resource for developing pharmaceuticals and functional foods. Specifically, Hericium erinaceus (He), thanks to its bioactive metabolites, exerts numerous healthy beneficial effects, such as reinforcing the immune system, counteracting ageing, and improving cognitive performance. Our previous works demonstrated the capabilities of two months of He1 standardised extract oral supplementation in preventing cognitive decline in elderly frail mice. Herein, we showed that this treatment did not change the overall gut microbiome composition but significantly modified the relative abundance of genera specifically involved in cognition and inflammation. Parallelly, a significant decrease in crucial markers of inflammation and cellular senescence, i.e., CD45, GFAP, IL6, p62, and γH2AX, was demonstrated in the dentate gyrus and Cornus Ammonis hippocampal areas through immunohistochemical experiments. In summary, we suggested beneficial and anti-inflammatory properties of He1 in mouse hippocampus through the gut microbiome-brain axis modulation.
RESUMO
Frailty during aging is an increasing problem associated with locomotor and cognitive decline, implicated in poor quality of life and adverse health consequences. Considering the microbiome-gut-brain axis, we investigated, in a longitudinal study, whether and how physiological aging affects gut microbiome composition in wild-type male mice, and if and how cognitive frailty is related to gut microbiome composition. To assess these points, we monitored mice during aging at five selected experimental time points, from adulthood to senescence. At all selected experimental times, we monitored cognitive performance using novel object recognition and emergence tests and measured the corresponding Cognitive Frailty Index. Parallelly, murine fecal samples were collected and analyzed to determine the respective alpha and beta diversities, as well as the relative abundance of different bacterial taxa. We demonstrated that physiological aging significantly affected the overall gut microbiome composition, as well as the relative abundance of specific bacterial taxa, including Deferribacterota, Akkermansia, Muribaculaceae, Alistipes, and Clostridia VadinBB60. We also revealed that 218 amplicon sequence variants were significantly associated to the Cognitive Frailty Index. We speculated that some of them may guide the microbiome toward maladaptive and dysbiotic conditions, while others may compensate with changes toward adaptive and eubiotic conditions.
Assuntos
Fragilidade , Microbiota , Animais , Bactérias/genética , Eixo Encéfalo-Intestino , Disbiose/microbiologia , Estudos Longitudinais , Masculino , Camundongos , Qualidade de VidaRESUMO
Gut microbiota is emerging as a key regulator of many disease conditions and its dysregulation is implicated in the pathogenesis of several gastrointestinal and extraintestinal disorders. More recently, gut microbiome alterations have been linked to neurodegeneration through the increasingly defined gut microbiota brain axis, opening the possibility for new microbiota-based therapeutic options. Although several studies have been conducted to unravel the possible relationship between Alzheimer's Disease (AD) pathogenesis and progression, the diagnostic and therapeutic potential of approaches aiming at restoring gut microbiota eubiosis remain to be fully addressed. In this narrative review, we briefly summarize the role of gut microbiota homeostasis in brain health and disease, and we present evidence for its dysregulation in AD patients. Based on these observations, we then discuss how dysbiosis might be exploited as a new diagnostic tool in early and advanced disease stages, and we examine the potential of prebiotics, probiotics, fecal microbiota transplantation, and diets as complementary therapeutic interventions on disease pathogenesis and progression, thus offering new insights into the diagnosis and treatment of this devastating and progressive disease.
Assuntos
Doença de Alzheimer , Microbioma Gastrointestinal , Doença de Alzheimer/diagnóstico , Doença de Alzheimer/terapia , Disbiose/terapia , Transplante de Microbiota Fecal , Microbioma Gastrointestinal/fisiologia , Humanos , PrebióticosRESUMO
Despite intensive study, neurodegenerative diseases remain insufficiently understood, precluding rational design of therapeutic interventions that can reverse or even arrest the progressive loss of neurological function. In the last decade, several theories investigating the causes of neurodegenerative diseases have been formulated and a condition or risk factor that can contribute is described by the gut-brain axis hypothesis: stress, unbalanced diet, and drugs impact altering microbiota composition which contributes to dysbiosis. An altered gut microbiota may lead to a dysbiotic condition and to a subsequent increase in intestinal permeability, causing the so-called leaky-gut syndrome. Herein, in this review we report recent findings in clinical trials on the risk factor of the gut-brain axis in Alzheimer's disease and on the effect of omega-3 supplementation, in shifting gut microbiota balance towards an eubiosis status. Despite this promising effect, evidences reported in selected randomized clinical trials on the effect of omega-3 fatty acid on cognitive decline in Alzheimer's disease are few. Only Mild Cognitive Impairment, a prodromal state that could precede the progress to Alzheimer's disease could be affected by omega-3 FA supplementation. We report some of the critical issues which emerged from these studies. Randomized controlled trials in well-selected AD patients considering the critical points underlined in this review are warranted.
Assuntos
Doença de Alzheimer/dietoterapia , Encéfalo/fisiopatologia , Cognição , Suplementos Nutricionais , Ácidos Graxos Ômega-3/administração & dosagem , Microbioma Gastrointestinal , Trato Gastrointestinal/microbiologia , Doença de Alzheimer/microbiologia , Doença de Alzheimer/fisiopatologia , Doença de Alzheimer/psicologia , Animais , Ensaios Clínicos como Assunto , Disbiose , Interações Hospedeiro-Patógeno , Humanos , Fatores de Proteção , Fatores de RiscoRESUMO
INTRODUCTION: Fiberoptic bronchoscopy is the gold standard to study and eventually treat tracheo-bronchial pathology. Performance of fiberoptic bronchoscopy enhances diagnostic precision and has not well documentated risks for the patients. This review examines the international literature of the last 30 yrs about the indication, complications and their prevention during bronchoscopy. MATERIALS AND METHODS: We reviewed by Internet 50 scientific articles, 23 of those were reporting or citing other experiences. We included as metasearch criteria "flexible", "fiberoptic", "bronchoscopy" and "complications" from 1974 to 2006, and as exclusions terms "pediatry", "pregnancy" and "urgency/emergency". Thus, we reported for every complication the incidence range, the characteristics and the indications for the bronchoscopy. DISCUSSION: On 107969 bronchoscopies, the incidence of complication of local anaesthesia was 0.3-0.5%; hypoxiaemia 0.2-21%; arrhythmia 1-10%; post-biopsy bleeding 0.12-7.5%; pneumothorax or pneumomediastinum 1-6%; fever 0.9-2.5%; death 0.1-0.2%. The majority of these complications were not life threatening. CONCLUSIONS: Flexible bronchoscopy is an extremely safe procedure as long as some basic precautions are taken: complications incidence may be reduced by accurate patient selection, correct indication to bronchoscopy with an adequate anaesthesia or analgosedation and the correct endoscope. Is safe and useful virtual bronchoscopy in selected cases. Equipe cooperation and the responsibility of performing endoscopes are basilar. The gain of informed consensus is imperative before the bronchoscopy.
Assuntos
Broncoscopia/efeitos adversos , Broncoscópios , Desenho de Equipamento , Tecnologia de Fibra Óptica , HumanosRESUMO
Non-coeliac/non-allergic gluten/wheat sensitivity (NCG/WS) is a gluten-related disorder, the pathogenesis of which remains unclear. Recently, the involvement of an increased intestinal permeability has been recognized in the onset of this clinical condition. However, mechanisms through which it takes place are still unclear. In this review, we attempt to uncover these mechanisms by providing, for the first time, an integrated vision of recent scientific literature, resulting in a new hypothesis about the pathogenic mechanisms involved in NCG/WS. According to this, the root cause of NCG/WS is a particular dysbiotic profile characterized by decreased butyrate-producing-Firmicutes and/or Bifidobacteria, leading to low levels of intestinal butyrate. Beyond a critical threshold of the latter, a chain reaction of events and vicious circles occurs, involving other protagonists such as microbial lipopolysaccharide (LPS), intestinal alkaline phosphatase (IAP) and wheat α-amylase trypsin inhibitors (ATIs). NCG/WS is likely to be a multi-factor-onset disorder, probably transient and preventable, related to quality and balance of the diet, and not to the presence of gluten in itself. If future studies confirm our proposal, this would have important implications both for the definition of the disease, as well as for the prevention and therapeutic-nutritional management of individuals with NCG/WS.
Assuntos
Bifidobacterium/crescimento & desenvolvimento , Doença Celíaca/microbiologia , Disbiose , Firmicutes/crescimento & desenvolvimento , Microbioma Gastrointestinal , Glutens/administração & dosagem , Intestinos/microbiologia , Triticum/efeitos adversos , Hipersensibilidade a Trigo/microbiologia , Animais , Bifidobacterium/metabolismo , Butiratos/metabolismo , Doença Celíaca/classificação , Doença Celíaca/diagnóstico , Doença Celíaca/imunologia , Medicina Baseada em Evidências , Firmicutes/metabolismo , Glutens/imunologia , Humanos , Absorção Intestinal , Permeabilidade , Prognóstico , Fatores de Risco , Triticum/imunologia , Hipersensibilidade a Trigo/classificação , Hipersensibilidade a Trigo/diagnóstico , Hipersensibilidade a Trigo/imunologiaRESUMO
AIM: Intestinal dysbiosis seems to be the leading cause of inflammatory bowel diseases, and probiotics seems to represent the proper support against their occurrence. Actually, probiotic blends and anti-inflammatory drugs represent a weapon against inflammatory bowel diseases. The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity. METHOD: Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single daily oral administration of mesalazine 1200 mg; 30 patients received a single daily oral administration of mesalazine 1200 mg and a double daily administration of a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4. The treatment was carried out for two years and the clinical response evaluated according to the Modified Mayo Disease Activity Index. RESULTS: All patients treated with combination therapy showed better improvement compared to the controls. In particular, the beneficial effects of probiotics were evident even after two years of treatment. CONCLUSIONS: A long-term treatment modality of anti-inflammatory drugs and probiotics is viable and could be an alternative to corticosteroids in mild-to moderate ulcerative colitis.
Assuntos
Colite Ulcerativa/tratamento farmacológico , Probióticos/uso terapêutico , Adulto , Idoso , Análise de Variância , Anti-Inflamatórios não Esteroides/uso terapêutico , Bifidobacterium bifidum , Método Duplo-Cego , Quimioterapia Combinada , Feminino , Humanos , Lactobacillus acidophilus , Ligilactobacillus salivarius , Masculino , Mesalamina/uso terapêutico , Pessoa de Meia-Idade , Resultado do TratamentoRESUMO
OBJECTIVE: To evaluate methods of diagnosis and treatment, and the long term survival of patients treated for bronchial carcinoid tumor by the review of recent literature. METHODS: The Authors conducted a retrospective study on internet-based-evidence of patients treated for bronchial carcinoid tumor since 1993 to 2004. Symptoms, diagnosis, operative approach and survival were assessed. CONCLUSIONS: On the basis of the review of the international literature, the Authors affirm that the 5 and 10-year probability of survival are closely linked to the histological type of carcinoid, to the presence of nodal and distant metastasis. Owing to the potential malignancy of these tumours, preference should be given to radical exeresis.